Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

This review aims to outline the most up-to-date knowledge of pancreatic adenocarcinoma
risk, diagnostics, treatment and outcomes, while identifying gaps that aim to stimulate further …

Background Exosomes from cancer cells or immune cells, carrying bio-macromolecules or
microRNAs (miRNAs), participate in tumor pathogenesis and progression by modulating …

Simple Summary Tumor mutational burden (TMB) represents the number of mutations per
megabase (muts/Mb) harbored by tumor cells in a given neoplasm, and can be determined …

Collagen type I alpha 1 (COL1A1), a member of the collagen family, is involved in epithelial–
mesenchymal transition, which is closely linked to malignant tumorigenesis. COL1A1 is …

Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait
is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases …

Pancreatic ductal adenocarcinoma (PDAC), an epithelial neoplasm derived from the
pancreatic ductal tree, is the most common histologic type of pancreatic cancer and …

Pancreatic cancer is one of the dreaded malignancies for both the patient and the clinician.
The five-year survival rate of pancreatic adenocarcinoma (PDA) is as low as 2% despite …

Undifferentiated carcinoma of the pancreas with osteoclast‐like giant cells (UCOGC) is
currently considered a morphologically and clinically distinct variant of pancreatic ductal …

The pathologist emerged in the personalized medicine era as a central actor in the definition
of the most adequate diagnostic and therapeutic algorithms. In the last decade …